» Carcinoid Heart Disease in Patients with Advanced Midgut NETs

MEET THE EXPERTS ALL PROGRAMMES DEVELOPED COLLABORATIONS CONTACT

Carcinoid Heart Disease in Patients with Advanced Midgut NETs – ENETS 2020 Poster #3

Dr. Faidon Laskaratos, Dr. Joakim Crona, Dr. Kira Oleinikov, Dr. Angela Lamarca, Dr. Alia Munir, Dr. Francesca Spada, Prof. Kjell Öberg, Dr. Teresa Alonso Gordoa, Dr. Wouter Zandee

Dr Faidon Laskaratos shares highlights of a retrospective multicentre evaluation of the outcomes and management of carcinoid heart disease in patients with advanced midgut NETs

Dr. Faidon Laskaratos

Gastroenterologist

Royal Free Hospital

United Kingdom (UK)

Dr. Joakim Crona

Clinical Oncology & Molecular Oncology

Uppsala Academic Hospital

Sweden

Dr. Kira Oleinikov

Endocrinologist

Hadassah Hebrew University Medical Center

Israel

Dr. Angela Lamarca

Medical Oncologist

The Christie NHS Foundation Trust

United Kingdom (UK)

Dr. Alia Munir

Endocrinologist

Sheffield Teaching Hospital NHS Foundation Trust

United Kingdom (UK)

Dr. Francesca Spada

Medical Oncologist

European Insititute of Oncology

Italy

Prof. Kjell Öberg

Endocrinologist

Uppsala University Hospital

Sweden

Dr. Teresa Alonso Gordoa

Medical Oncologist

Hospital Universitario Ramón y Cajal

Spain

Dr. Wouter Zandee

Endocrinologist

University Medical Center Groningen

Netherlands

Dr. Kira Oleinikov

Endocrinologist

Hadassah Hebrew University Medical Center

Israel

Dr. Kira Oleinikov, MD Senior physician, Neuroendocrine Tumor Unit and ENETS Center of Excellence, Endocrinology Department, Division of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. Following an initial training in molecular biology, Dr. Kira Oleinikov successfully completed an internal medicine and endocrinology specialization in 2017. In August 2018, Kira joined the Neuroendocrine Tumor Unit & ENETS Center of Excellence team at Hadassah-Hebrew University Medical Center in Jerusalem, one of the major clinical and research units in NETs internationally, as a full-consultant position. Kira is actively involved in all programs running at the Hadassah NET unit, including clinical programs (seeing NET patients in the clinic/departments or as part of the regular patient follow-up/recruitment inside clinical trials); NET laboratory research; teaching programs (both medical and post-graduate students at the Hadassah Faculty of Medicine); NET patient's advocacy group activities, and more. Kira is a member of the European Neuroendocrine Tumor Society (ENETS) and the Israeli Endocrine Society. Kira's sharp intellectual abilities driven her to a variety of academic achievements during her fellowship in molecular biology at the Hebrew University. She is continuously involved in the diagnostic and the therapeutic decision-making process of NET patients with a variety of tumors, and established herself already as a highly prepared clinician in the field. Nowadays, Kira's main research interest is focused on the evaluation of different treatment approaches to pancreatic NETs, as well as in developing new biomarkers for lung carcinoids. Additionally, she spends a significant part of her time in the unit basic research laboratory, aiming to examine the possible anti-tumorigenic effect of different drug combinations in a NET liver metastasis mice model, in an attempt to overcome drug-resistance. At a personal level, the combination of knowledge, tenacity, and good communications skills found in Kira is truly unique, making her an excellent partner for the COR2E program in NETs.

Dr. Kira Oleinikov has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Dr. Angela Lamarca

Medical Oncologist

The Christie NHS Foundation Trust

United Kingdom (UK)

Dr Angela Lamarca is a Medical Oncologist (MD, PhD, MSc), specialised in gastrointestinal malignancies (hepato-pancreato-biliary (HPB) and neuroendocrine tumours (NETs)). She completed her training in Medical Oncology (including her PhD) in Spain (Hospital Universitario La Paz, Madrid). She moved to The Christie NHS Foundation Trust (Manchester, United Kingdom) in 2013, where she completed a 4-year fellowship programme in HPB and NETs; during this period she received funding from ESMO (European Society for Medical Oncology) Translational Fellowship Programme, Pancreatic Cancer Research Fund and The Spanish Society of Medical Oncology (SEOM) Fellowship Grant Programme. Dr Lamarca has completed a Masters Degree in Molecular Biology of Cancer and a second Masters Degree in Biostatistics. She was awarded with an American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator Award in 2017 and was appointed as a Consultant in Medical Oncology at The Christie NHS Foundation Trust in May 2017 where she continues her Clinical and Translational Research career in HPB and NETs. She is actively involved in clinical trial design with special interest in NETs and HPB, focused on achieving a better understanding of these malignancies and identification of new therapies for improving patients’ outcome. Dr Angela Lamarca is a member of the EORTC Gastrointestinal Cancer Group and a faculty member of the ESMO Neuroendocrine, Endocrine Neoplasms and CUP Group.

Dr. Angela Lamarca has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Dr. Alia Munir

Endocrinologist

Sheffield Teaching Hospital NHS Foundation Trust

United Kingdom (UK)

Alia Munir trained in Medicine at the University of Wales College of Medicine and began her basic clinical training in Cardiff and South Wales. She then began her specialist training in Guy’s and St Thomas’ London and later completed her higher medical training in Diabetes, Endocrinology and General Internal Medicine at Sheffield Teaching Hospitals (STH). She was awarded The Society for Endocrinology Clinical Trust Research Fellowship and obtained a PhD in Professor Newell-Prices’ laboratory, focussing on RNA interference as a Therapy for Cushing’s Disease, leading to a patent and orphan drug designation. She was also awarded the Yorkshire Enterprise Fellowship. She was chair of the Young Endocrinologists Scientific Steering Committee for the Society for Endocrinology during this time. She was appointed Consultant in Diabetes and Endocrinology in Pinderfields Hospital, Mid Yorkshire 2011-2015. She was also appointed Consultant Endocrinologist in STH and coordinated Sheffield’s successful European Neuroendocrine Tumour Society Centre of Excellence award in 2016. She has lead in a joint working partnership with Novartis and been part of the 4th Wave Education programme with Ipsen. Dr Munir’s main clinical interests are in neuroendocrinology and high risk diabetic pregnancy, and is responsible for general medical inpatients and participates in the medical take.

Dr. Alia Munir has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Dr. Francesca Spada

Medical Oncologist

European Insititute of Oncology

Italy

Dr. Francesca Spada is a Medical Oncologist at the Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumor, European Institute of Oncology (IEO IRCCS, Milan, Italy). She has been part of this team for the last eight years. Francesca completed her specialty in Medical Oncology in 2011 at the University of Sassari. She is involved in clinical management of patients affected by neuroendocrine neoplasms (NENs), educational activities in NENs, and she is also involved in NENs translational research projects. In January 2019, she plans to finish her PhD in Translation and Experimental Medicine at the University of Insubria (Varese, Italy), focusing on the development of mixed adeno-neuroendocrine carcinomas (MANECs). She is also responsible for the IEO Neuroendocrine Multidisciplinary Group activity as quality coordinator. She is a member of the Italian Association of Medical Oncology (AIOM) while also serving on the AIOM Young Directive Board. She is a member of the Directive Board of the Italian Association of Neuroendocrine Tumors (Ita.NET). She is also member of the European Neuroendocrine Tumor Society (ENETS), the North American Neuroendocrine Society (NANETS), and the European Society of Medical Oncology (ESMO). In the last three years, Francesca co-authored several peer-reviewed studies, in particular a notable Italian multicenter analysis of oxaliplatin-based chemotherapy in NET patients as a lead author, and an Italian multicenter study of octreotide and everolimus as first-line therapy in patients with well-differentiated NETs.

Dr. Francesca Spada has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Prof. Kjell Öberg

Endocrinologist

Uppsala University Hospital

Sweden

Dr. Kjell Öberg is Professor of Endocrine Oncology at the Medical Faculty of Uppsala University. He was the former head of the Department of Endocrine Oncology, University Hospital, and he is a specialist in endocrinology and internal medicine. He founded the Department of Endocrine Oncology at Uppsala University Hospital and has 40 years’ experience in the field of neuroendocrine tumors. Between 1986 and 1992 he was clinical associate director of the Ludwig Institute for Cancer Research. From 1998 to 2002 he was chairman of the Department of Medical Sciences at the Medical Faculty of Uppsala University. July 2002 until June 2008 he was the Dean of the Medical Faculty. He was the chairman of the Centre of Excellence of Endocrine Tumors and Vice chairman of the Department of Endocrine Oncology, University Hospital, Uppsala until May 2013, at present time he is senior advisor at the same department. Currently, Adjunct Professor of Surgery at Vanderbilt University, Nashville, USA. Dr. Öberg was one of the founders and coordinator of the European Neuroendocrine Tumor Network (ENET) 1995-2000 and was past chairman of the Nordic Neuroendocrine Tumor Group. He has pioneered the treatment of carcinoid tumor patients with interferon and somatostatin analogues and developed assays for tumor markers such as Chromogranin A and radiological procedures, including specialized PET scans. In 1988 he was the first to describe a genetic deletion in multiple endocrine neoplasia Type 1 (MEN1). Dr. Öberg has given many hundreds of presentations at international meetings and published more than 500 papers within his research field, H-factor 67 and 14,850 citations. In addition he is the author of numerous chapters on Carcinoid tumors in several international textbooks including William’s Textbook of Endocrinology, Leslie de Groot’s Textbook of Endocrinology, Clinical Endocrinology and Fordtran’s Textbook of Gastroenterology. Dr. Öberg is Editor-in Chief of World Journal of Gastroenterolgy (WJG). In 1991 Dr. Öberg received the European Interferon Research reward. In 2003 he received the award “Eminent Scientist Year 2003” by the International Research Promotion Council (IRPC) and World Scientist Forum and in 2004 he was awarded the European Gold Medal in Endocrinology from the English Endocrine Society. In November 2006 he received the Harry Boström Award Lecture at Swedish Medical Society, and in 2011 the University Hospital Clinical Research Award. In 2014 he received the Rudbeck Medallion for excellence in research and the Life Time Achievement Award from North American Neuroendocrine Society. January 2017 Dr. Öberg was awarded with The Swedish Endocrine Society Gold Medal for prominent research and clinical activities and in March 2017 he received Lifetime Achievement Award by European Neuroendocrine Tumor Society (ENETS). In October of 2017, Lifetime Achievement from Asian Pacific Neuroendocrine Tumor Society (AP-NETS). Dr. Öberg is a member of the Royal Society of Sciences, member of Swedish Society of Medical Research, Honorary member of Finnish Oncology Society, Finnish Endocrine Society and Honorary member of Spanish Neuroendocrine NET-work. Dr. Öberg is Vice President of ENETS since March 2012 and also a member of NANETS Advisory Board as well as several other national and international research and scientific boards and many scientific journal review boards.

Prof. Kjell Öberg has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Dr. Teresa Alonso Gordoa

Medical Oncologist

Hospital Universitario Ramón y Cajal

Spain

Dr. Teresa Alonso Gordoa is a Medical Oncologist at the Medical Oncology Department of the Hospital Universitario Ramón y Cajal in Madrid. She finalized the degree of medicine by the University of Navarre in 2008 and the medical oncology specialization by the Hospital Universitario Clínico San Carlos in 2013. She is specialized in the care of patients with genitourinary, germ cell and endocrine tumors and in the early drug development unit. In addition, she is a member of the Spanish Society of Medical Oncology (SEOM), the European Society for Medical Oncology (ESMO), the Spanish Society of Genitourinary Oncology (SOGUG), the Germ Cell Group (GG) and the Spanish Group of Neuroendocrine Tumors (GETNE). She participates actively in research projects and clinical trials with international impact. She is a member of the honorary faculty of the University of Alcalá and a reviewer of indexed international journals. She has presented communications in national and international congresses and has participated in the publication of scientific articles in national and international journals.

Dr. Teresa Alonso Gordoa has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

time | open 5 min | Apr 2020

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

download resources

DOWNLOAD THE POSTER

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

NET CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Ipsen and from Eisai Europe Limited.

Other programmes of interest

Prof Valentina Guarneri

Interactive patient case

28 min

(TEST) Oral SERDs: New Endocrine Therapy Options in ER+ Advanced ...

Sep 2023

Prof. Viktor Grünwald

Interactive patient case

11 min

Optimising treatment for advanced RCC

Jun 2023

Prof. David Hong

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.